miRagen Therapeutics Inc Gets a Buy Rating from Chardan Capital

By Jason Carr

In a report released today, Madhu Kumar from Chardan Capital reiterated a Buy rating on miRagen Therapeutics Inc (NASDAQ: MGEN). The company’s shares closed on Friday at $11.56.

According to TipRanks.com, Kumar is a 4-star analyst with an average return of 7.2% and a 62.0% success rate. Kumar covers the Healthcare sector, focusing on stocks such as Arbutus Biopharma Corporation, Iovance Biotherapeutics Inc, and Achillion Pharmaceuticals.

miRagen Therapeutics Inc has an analyst consensus of Strong Buy, with a price target consensus of $19.

The company has a one year high of $18 and a one year low of $1.80. Currently, miRagen Therapeutics Inc has an average volume of 62.19K.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Signal Genetics, Inc. is a commercial stage, molecular diagnostic company. It provides innovative diagnostic services that help physicians make better-informed decisions concerning the care of their patients suffering from cancer. The company was founded in January 2010 and is headquartered in Carlsbad, CA.